Whether we acknowledge it or not, health care stocks are part of one of the most significant sectors in the stock market today. The companies in the industry range from those that sell medical supplies, offer medical services, or even provide real estate for medical organizations. Well, it goes without saying that health care stocks have been under the spotlight for the past year due to the global pandemic. Even without the pandemic, it is an essential service that everybody needs at some point in one’s life.
As technology advances, the health care industry is also evolving. Recently, we saw companies such as Intellia Therapeutics Inc (NASDAQ: NTLA) having a breakthrough in precision editing of a gene in target tissue in humans. This has led to the company’s stock soaring by over 90% over the past month. Gene editing could potentially unlock the door to treating a wide array of other genetic diseases. Given how rapidly health care is advancing, it would be beneficial to be keeping tabs on the industry. So, here’s a list of some of the top health care stocks in the stock market now.Best Health Care Stocks To Buy [Or Sell] Today
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
- Apollo Medical Holdings Inc (NASDAQ: AMEH)
- IVERIC bio Inc (NASDAQ: ISEE)
- Alector Inc (NASDAQ: ALEC)
First up, we have a biopharmaceutical company that specializes in the treatment of serious medical conditions, Regeneron. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and has product candidates in other areas such as rheumatoid arthritis, asthma, and many other infectious diseases. REGN stock has risen over 20% since the start of the year.
In June, the company along with Intellia Therapeutics, Inc. announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001. This is huge progress for what is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The results appear to indicate that NTLA-2001 has the potential to halt and reverse the complications of ATTR. Hence, this is a significant milestone for both companies and the health care industry itself. This marks the first-ever clinical data that suggest we can precisely edit target cells within the body.
Furthermore, Regeneron also recently discovered rare genetic mutations in the GPR75 gene associated with protection against obesity. Scientists from the company found that individuals who have at least one inactive copy of the gene have lower BMI, and face a 54% lower risk of obesity than those without the mutation. This discovery provides hope in combating global health challenges that are as prevalent as obesity. With all these exciting developments surrounding the company, would you be buying REGN stock any time soon?Source: TD Ameritrade TOS
Read MoreApollo Medical Holdings Inc
Next, we have Apollo Medical Holdings. It is a physician-centric integrated health management company working to provide coordinated, outcomes-based medical care. Put simply, it provides care coordination services to each constituent of the health care delivery system that includes patients, families, primary care physicians, and physician groups. AMEH stock has been on a strong bullish momentum over the past year. Believe it or not, it has skyrocketed by more than 350% during that time.
Last month, the company announced that its affiliate Allied Pacific of California IPA (APC), will be partnering with Shriners Children’s Southern California in the opening of a new satellite clinic in Downtown Los Angeles on July 9, 2021. The specialty pediatric care clinic will provide patients with access to pediatric physicians. Hence this would serve more children and families by bringing services into their neighborhood.
Also, it is also worth noting that the company has been added to the S&P SmallCap 600 index on June 15, 2021. Investors could see this as a testament to the company’s commitment to long-term growth and financial performance as the leader in value-based health care management. So, would you consider AMEH stock to be a top health care stock in the stock market now?Source: TD Ameritrade TOS IVERIC bio Inc
Moving on, we have an up-and-coming biopharmaceutical company, IVERIC. Essentially, it focuses on the discovery and development of treatment options for retinal diseases. As of now, the company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). ISEE stock has soared by more than 40% over the past week. Now, let us see what served as the catalyst for this movement.
Earlier in June, the company shared positive post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura in dry age-related macular degeneration (AMD). GATHER1 18 month post-hoc analyses show that Zimura 2 mg can potentially impact earlier stages of dry AMD before geographic atrophy (GA). In summary, the analysis shows that there is a relative risk reduction in the rate of progression to GA.
Furthermore, on Tuesday of this week, IVERIC announced that it has received a written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the overall design of GATHER2. Similar to the company’s completed GATHER1 clinical trial, GATHER2 is designed to be an adequate and well-controlled clinical trial. If it turns out positive, it would support a New Drug Application for Zimura in the treatment of GA secondary to AMD. All things considered, would you buy into the future of ISEE stock?Source: TD Ameritrade TOS Alector Inc
Alector is a clinical-stage biopharmaceutical company. The company focuses on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. It is developing therapies to simultaneously counteract these pathologies by restoring healthy immune function to the brain. ALEC stock is yet another health care stock that has been making waves lately. Within the past week, it has climbed by almost 90% and currently trades at $39.49 as of Wednesday’s closing bell.
The recent hike is largely attributed to its recent strategic global collaboration with GlaxoSmithKline plc (NYSE: GSK) for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. Hence, it will bring together Alector’s leading immuno-neurology expertise with GSK’s research and development focus on the science of the immune system and human genetics.
Moreover, Citigroup’s analyst has also recently raised her price target to $43 per share from the previous $31. This reiterates the buy recommendation on the stock. With any biotech company, the goal is to partner with a larger company to provide capital for its research. Well, Alector appears to have succeeded on that front. So, would you consider investing in ALEC stock?Source: TD Ameritrade TOS